Merck Sharp & D — Medicare Part D spending
Rank #12 by attributed Part D spend · 36 tracked drugs · CMS data year 2023
About $6,156,412,182 of Medicare Part D spending in 2023 is attributed to Merck Sharp & D across the 36 of its drugs tracked here, ranking it #12 among manufacturers on this site. Its biggest Part D drug is Januvia at $4,090,836,821. Attribution uses the CMS manufacturer lists and is indicative, not definitive. These are aggregate program figures, not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Merck Sharp & D drugs in Medicare Part D (2023)
| Brand | Generic | Total spend | Per dosage unit | Beneficiaries | Spend rank |
|---|---|---|---|---|---|
| <a href="/drug/januvia-sitagliptin-phosphate/">Januvia</a> | Sitagliptin Phosphate | $4,090,836,821 | $18.88 | 843,391 | #9 |
| <a href="/drug/janumet-sitagliptin-phos-metformin-hcl/">Janumet</a> | Sitagliptin Phos/Metformin HCl | $798,865,849 | $9.45 | 168,527 | #65 |
| <a href="/drug/janumet-xr-sitagliptin-phos-metformin-hcl/">Janumet XR</a> | Sitagliptin Phos/Metformin HCl | $392,139,531 | $12.79 | 89,316 | #142 |
| <a href="/drug/belsomra-suvorexant/">Belsomra</a> | Suvorexant | $161,202,978 | $14.98 | 86,387 | #277 |
| <a href="/drug/isentress-raltegravir-potassium/">Isentress</a> | Raltegravir Potassium | $130,537,595 | $33.53 | 7,475 | #325 |
| <a href="/drug/dificid-fidaxomicin/">Dificid</a> | Fidaxomicin | $127,162,103 | $244.78 | 21,562 | #334 |
| Keytruda | Pembrolizumab | $116,820,430 | $1,449.53 | 1,523 | #354 |
| Prevymis | Letermovir | $73,949,062 | $258.48 | 2,391 | #485 |
| Pifeltro | Doravirine | $70,629,257 | $58.91 | 4,371 | #507 |
| Welireg | Belzutifan | $59,823,810 | $325.38 | 453 | #563 |
| Verquvo | Vericiguat | $34,422,269 | $22.41 | 8,218 | #733 |
| Isentress Hd | Raltegravir Potassium | $26,641,375 | $33.42 | 1,463 | #843 |
| Steglatro | Ertugliflozin Pidolate | $18,207,799 | $11.44 | 11,552 | #995 |
| Delstrigo | Doravirine/Lamivu/Tenofov Diso | $16,119,607 | $89.55 | 722 | #1031 |
| Zerbaxa | Ceftolozane/Tazobactam | $12,776,957 | $20.11 | 967 | #1140 |
| Lagevrio (Eua) | Molnupiravir | $11,460,715 | $0.75 | 378,158 | #1177 |
| Zolinza | Vorinostat | $3,402,208 | $132.24 | 61 | #1645 |
| Gardasil 9 | HPv Vaccine 9-Valent/PF | $2,173,589 | $605.18 | 4,779 | #1816 |
| M-M-R II Vaccine | Measles,Mumps,Rubella Vacc/PF | $1,492,884 | $112.60 | 11,583 | #1940 |
| Steglujan | Ertugliflozin/Sitagliptin Phos | $1,376,725 | $18.68 | 372 | #1970 |
| Segluromet | Ertugliflozin/Metformin | $1,266,291 | $5.72 | 722 | #2007 |
| Vaqta | Hepatitis A Virus Vaccine/PF | $1,191,887 | $102.64 | 10,556 | #2031 |
| Recarbrio | Imipenem/Cilastatin/Relebactam | $1,052,578 | $118.43 | 32 | #2078 |
| BCG (Tice Strain) | BCG Live | $721,870 | $164.62 | 709 | #2221 |
| Zinplava | Bezlotoxumab | $631,513 | $95.80 | 152 | #2268 |
| Varivax Vaccine | Varicella Vaccine Live/PF | $508,729 | $190.46 | 2,193 | #2351 |
| Zepatier | Elbasvir/Grazoprevir | $467,651 | $273.80 | 23 | #2385 |
| Pregnyl | Chorionic Gonadotropin, Human | $254,690 | $96.72 | 196 | #2561 |
| Recombivax Hb | Hepatitis B Virus Vaccine/PF | $77,899 | $99.00 | 610 | #2858 |
| Emend | Aprepitant | $61,588 | $293.23 | 22 | #2927 |
| Cancidas | Caspofungin Acetate | $55,072 | $142.31 | — | #2953 |
| Pedvaxhib | Haemph B Polysac Conj-Menin/PF | $38,765 | $93.07 | 545 | #3029 |
| Primaxin | Imipenem/Cilastatin Sodium | $21,562 | $5.28 | 22 | #3166 |
| Invanz | Ertapenem Sodium | $13,802 | $73.03 | 32 | #3240 |
| Proquad | Measles,Mumps,Rub,Varicella/PF | $5,089 | $275.10 | 21 | #3376 |
| Stromectol | IVermectin | $1,634 | $4.97 | 31 | #3495 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Frequently asked questions
How much Medicare Part D spending does Merck Sharp & D get?
In 2023, about $6,156,412,182 of Medicare Part D spending is attributed to Merck Sharp & D across the 36 of its drugs tracked here. Its biggest is Januvia at $4,090,836,821. This is gross program spending, not what patients pay. Source: CMS, data year 2023.
What is Merck Sharp & D's top Medicare Part D drug?
Among the drugs tracked here, Merck Sharp & D's highest Part D spending in 2023 is Januvia at $4,090,836,821 (national rank #9 by total spend).
Is manufacturer attribution exact?
No. CMS may list multiple manufacturers per drug, and labeler relationships change over time. We attribute each drug to its primary listed manufacturer, so these rollups are indicative rather than definitive. Always check the underlying CMS file for a specific drug.
Keep exploring
Data: CMS Medicare Part D Spending by Drug (data year 2023), U.S. public domain. Aggregate program spending, not prices. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-21